Pfizer Inc Announces Positive Topline Results from Phase 3 MagnetisMM-5 Study Evaluating Elrexfio as Monotherapy in Adults with Relapsed or Refractory Multiple Myeloma May 01
Pfizer Inc. Enters into Settlement Agreements with Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd for VYNDAMAX Apr 30
Fourth quarter dividend of US$0.43 announced Apr 26
Astellas Pharma Inc. And Pfizer Inc. Receive U.S. FDA Priority Review For PADCEV And Keytruda As Perioperative Treatment For Muscle-Invasive Bladder Cancer Apr 20
Pfizer Inc. to Report Q1, 2026 Results on May 05, 2026 Mar 24
Pfizer Inc. and Valneva SE Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 Valor Trial Mar 23
Pfizer Inc Announces Positive Topline Results From Phase 3 Talapro-3 Study Of Talzenna In Combination With Xtandi Mar 19
Pfizer Inc., Annual General Meeting, Apr 23, 2026 Mar 13
Pfizer Inc. Reports Positive Phase 2 Results for tilrekimig (PF-07275315) in Atopic Dermatitis Mar 10
New major risk - Financial position Mar 02
Pfizer Inc. and Astellas Pharma Inc. Announce Positive Results from the Phase 3 EV-304 Clinical Trial Feb 28
Pfizer Inc. Announces U.S. FDA Grants Full Approval to its BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer Feb 25
Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer Feb 17
Pfizer Inc. Announced That FDA Has Accepted and Granted Priority Review for the Company's Supplemental Biologics License Application Feb 06
New major risk - Revenue and earnings growth Feb 05
Full year 2025 earnings released: EPS: US$1.36 (vs US$1.42 in FY 2024) Feb 04
Third quarter dividend of US$0.43 announced Jan 12
Pfizer Inc.'s BRAFTOVI Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer Jan 12
Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio Jan 08
Pfizer Inc. to Report Q4, 2025 Results on Feb 03, 2026 Dec 19
Third quarter dividend of US$0.43 announced Dec 17
Pfizer Inc. Provides Earnings Guidance for the Full Year 2026 Dec 17
Pfizer Inc. Declares First-Quarter 2026 Dividend, Payable on March 6, 2026 Dec 13
Pfizer Inc. Announces Detailed Results from the Phase 3 HER2CLIMB-05 Trial of the Tyrosine Kinase Inhibitor TUKYSA (Tucatinib) Dec 11
Pfizer Inc. Presents Results from the Phase 3 BASIS Study Evaluating HYMPAVZI for Adults and Adolescents Dec 07
U.S. FDA Approves PADCEV plus Keytruda for Certain Patients with Bladder Cancer Nov 22
Pfizer Inc. (NYSE:PFE) completed the acquisition of Metsera, Inc. (NasdaqGS:MTSR) from Arch Venture Partners, L.P., Population Health Partners, LLC and others. Nov 14
Pfizer Reportedly Looks to Sell Stake in Pandemic Vaccine Partner BioNTech Nov 13
New minor risk - Dividend sustainability Nov 05
Third quarter 2025 earnings released: EPS: US$0.62 (vs US$0.79 in 3Q 2024) Nov 05
Pfizer Inc. Reaffirms Earnings Guidance for the Full Year of 2025 Nov 04
Pfizer Inc. Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition Nov 01
Upcoming dividend of US$0.43 per share Oct 31
Pfizer Inc. Announces Positive Topline Results from the Phase 3 Her2climb-05 Trial of First-Line Combination Therapy with the Tyrosine Kinase Inhibitor Tukysa®? Oct 15
Second quarter dividend of US$0.43 announced Oct 13
Hearing Against Pfizer Set for 29 September in Contraceptive ‘Depo-Provera’ Multidistrict Litigation Overseen by Levin Papantonio Sep 26
Pfizer Inc. to Report Q3, 2025 Results on Nov 04, 2025 Sep 23
New major risk - Revenue and earnings growth Sep 23
Arbutus Pharma Corp. and Genevant Sciences GmbH Provides Lawsuit Update Sep 12
Nastlaw LLC and Direct Purchaser Plaintiffs Announce Additional Settlements in Re Generic Pharmaceutical Pricing Antitrust Litigation Sep 11
Pfizer Inc. and BioNTech SE Announce Topline Data Demonstrating Robust Immune Response with Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula Sep 08
Olema Pharmaceuticals, Inc. Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer Sep 03
Enanta Pharmaceuticals, Inc. Files Patent Infringement Suit Against Pfizer Inc. in the Unified Patent Court of the European Union Aug 20
PADCEV Plus KEYTRUDA Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery Aug 12
Second quarter 2025 earnings released: EPS: US$0.51 (vs US$0.004 in 2Q 2024) Aug 07
Pfizer Inc. Reaffirms Earnings Guidance for the Full Year of 2025 Aug 05
BioNTech SE and Pfizer Inc. Announces Collaboration with Pfizer to Develop COVID-19 Vaccine, BNT162b2 mRNA Vaccine Jul 25
Pfizer's 'Depo-Provera' Increases Risk of Brain Tumours 3.5 Times Compared to Combined Birth Control Pill Jul 24
Upcoming dividend of US$0.43 per share Jul 18
Pfizer Inc. and Astellas Pharma Inc. Announce Positive Topline Results from the Overall Survival (OS) Analysis from the Phase 3 EMBARK Study Evaluating XTANDI Jul 10
First quarter dividend of US$0.43 announced Jul 02
Arvinas and Pfizer Announce Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer Jun 06
Pfizer Inc. Announces Statically Significant and Clinically Significant Results from the Phase 3 BREAKWATER Trial Evaluating BRAFTOVI®? (Encorafenib) in Combination with Cetuximab and mFOLFOX6 May 30
Case Management Conference in the Depo-Provera Legal Action Against Pfizer Inc May 29
First quarter 2025 earnings released: EPS: US$0.52 (vs US$0.55 in 1Q 2024) Apr 30
Pfizer Inc. Reaffirms Earnings Guidance for the Year 2025 Apr 29
Fourth quarter dividend of US$0.43 announced Apr 27
Pfizer Inc. Declares Second-Quarter 2025 Dividend, Payable on June 13, 2025 Apr 24
ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO to Include Adults Aged 50 to 59 At Increased Risk of Disease Apr 17
Pfizer Inc. Provides Update on Oral Glp-1 Receptor Agonist Danuglipron Apr 14
Entwistle & Cappucci LLP Files Securities Class Action Against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC and Pfizer, Inc Apr 05
European Commission Approves Pfizer's RSV Vaccine ABRYSVO to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease Apr 01
Pfizer Inc. to Report Q1, 2025 Results on Apr 29, 2025 Mar 18
Pfizer Inc., Annual General Meeting, Apr 24, 2025 Mar 14
Arvinas, Inc. and Pfizer Inc. Announce Positive Topline Results from Phase 3 Veritac-2 Clinical Trial Mar 11
Pfizer’s TALZENNA in Combination with XTANDI Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer Feb 14
U.S. FDA Approves Pfizer's ADCETRIS Combination Regimen for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Feb 13
Pfizer Inc. and Astellas Pharma Inc.'s PADCEV plus KEYTRUDA Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer Feb 11
Full year 2024 earnings released: EPS: US$1.42 (vs US$0.38 in FY 2023) Feb 05
Pfizer’s Braftovi Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 Breakwater Trial Feb 03
Pfizer Inc. Announces Positive Results from the Phase 3 Breakwater Trial Evaluating Braftovi® (Encorafenib) in Combination with Cetuximab and Mfolfox6 Jan 27
Third quarter dividend of US$0.43 announced Jan 20
Upcoming dividend of US$0.43 per share Jan 20
Pfizer Intends to Sell Approximately 700 Million Ordinary Shares in Haleon Jan 15
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer Jan 10
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer Dec 21
Pfizer Inc. to Report Q4, 2024 Results on Feb 04, 2025 Dec 19
Pfizer Inc. Provides Earnings Guidance for the Fiscal Year 2025; Reaffirms Earnings Guidance for the Year 2024 Dec 18
Third quarter dividend of US$0.43 announced Dec 16
Pfizer Inc. Declares First-Quarter 2025 Dividend, Payable on March 7, 2025 Dec 13
Pfizer’s IBRANCE in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer Dec 12